A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248
NCT00094029
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
- Histologically proven Gastrointestinal Stomal Tumor (GIST) that is not amenable to standard therapy
- Undergone screening and found to be ineligible for participation in ongoing SU011248 clinical studies
- Patient judged to have potential to derive clinical benefit from SU011248 treatment by the treating physician
- Failed prior treatment with imatinib mesylate, defined as either progression of disease or significant toxicity during treatment with imatinib mesylate that precluded further treatment
- Male or Female, 18 years or older
- Resolution of all acute toxicities of prior therapies
- Adequate organ function
- Symptomatic congestive heart failure, myocardial infarction, or coronary artery bypass
graft in the last 6 months, or ongoing severe or unstable angina or any unstable
arrhythmia requiring medication
- Symptomatic central nervous system metastases
- Serious acute or chronic illness
- Current treatment on another clinical trial
- Pregnant or breastfeeding.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Duarte, California
- Pasadena, California
- San Francisco, California
- Santa Monica, California
- Washington, District of Columbia
- Gainesville, Florida
- Gainsville, Florida
- Miami, Florida
- Tampa, Florida
- Niles, Illinois
- Park Ridge, Illinois
- Boston, Massachusetts
- New Bedford, Massachusetts
- Detroit, Michigan
- Detroit, Michigan
- Farmington Hills, Michigan
- Minneapolis, Minnesota
- Rochester, Minnesota
- Creve Coeur, Missouri
- St. Louis, Missouri
- St. Louis, Missouri
- Bronx, New York
- Buffalo, New York
- New York, New York
- New York, New York
- Durham, North Carolina
- Portland, Oregon
- Portland, Oregon
- Dallas, Texas
- Seattle, Washington
- Seattle, Washington
- Madison, Wisconsin
- Burnos Aires,
- Camperdown, New South Wales
- Randwick, New South Wales
- Auchenflower, Queensland
- Bedford Park, South Australia
- East Melbourne, Victoria
- Nedlands, Western Australia
- Ashford SA,
- Auchenflower QLD,
- Graz,
- Wien,
- Brussels,
- Leuven,
- Calgary, Alberta
- Vancouver, British Columbia
- Winnipeg, Manitoba
- St. John's, Newfoundland and Labrador
- Toronto, Ontario
- Montreal, Quebec
- Santiago, RM
- Bogota, Cundinamarca
- Brno,
- Praha 5,
- Aarhus C,
- Herlev,
- Helsinki,
- Bordeaux Cedex,
- Lyon,
- Marseille,
- Berlin,
- Duesseldorf,
- Koeln,
- Muenchen,
- Thessaloniki,
- Happy Valley,
- Hong Kong,
- Budapest,
- New Delhi, Delhi
- Mumbai, Maharashtra
- Vellore, Tamil Nadu
- Tel Hashomer,
- Tel-Aviv,
- Aviano (PN),
- Aviano, PN,
- Bologna,
- Candiolo (TO),
- Genova,
- Milano,
- Milano,
- Milano,
- Torino,
- Seoul,
- Seoul,
- Mexico, DF
- Guadalajara, Jalisco
- Groningen, Gr
- Leiden,
- Oslo,
- Warszawa,
- Singapore,
- Singapore,
- Bratislava,
- Oviedo, Asturias
- L'Hospitalet de Llobregat, Barcelona
- Barcelona,
- Madrid,
- Sevilla,
- Valencia,
- Göteborg,
- Lausanne,
- Kaohsiung Hsien,
- Taipei,
- Taipei,
- Taipei,
- Ratchatawi, Bangkok
- Bangkok,
- Ankara,
- Inciralti / IZMIR,
- Istanbul,
- Leeds, England
- London,
- London,
- Manchester,
- Newcastle upon Tyne,
- Newcastle-Upon-Tyne,
- Caracas, Distrito Capital
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248 | |||
| Brief Summary | The purpose of this study is to permit access to SU011248 for treatment use by patients with GIST given the following conditions: a) patients undergo screening, but are not eligible for participation in ongoing clinical studies such as A6181004; AND b) patients have GIST which standard treatments have not been able to control with acceptable toxicity AND c) patients have the potential to derive clinical benefit from treatment with SU011248. | |||
| Detailed Description | Given that an Expanded Access study does not meet the definition of a controlled clinical investigation, and as such, is not considered an applicable drug clinical trial per NIH, Basic Results for such studies are not required to be reported. Protocol A6181036 has been identified as an Expanded Access trial, and has been registered to ClinicalTrials.gov, however Basic Results will not be posted. | |||
| Study Type | Expanded Access | |||
| Intervention | Drug: Sutent
Sutent, 25, 37.5, or 50 mg daily | |||
| Publications * |
| |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Expanded Access Status | Approved for marketing | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Norway, Poland, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Venezuela | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT00094029 | |||
| Responsible Party | Pfizer | |||
| Study Sponsor | Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | March 2012 | |||